Varian develops integrated radiation therapy technology:
This article was originally published in Clinica
Executive Summary
Varian Medical Systems has developed what it claims is the first image-guided radiation therapy system able to perform both conventional and stereotactic approaches for treating cancer. The Trilogy system is currently pending 510(k) clearance by the US FDA. The Salt Lake City, Utah firm says that having one flexible system would be a cost-effective means for clinics to expand case mix and treatment modality. Varian has also announced a new version of its VARiS Vision radiation oncology management software, which is designed to simplify treatment-planning steps.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.